![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Patient-reported outcomes (PROs) after 1 year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): The BICSTaR cohort
|
|
|
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
H Knechten1, C Stephan2, M Waizmann3, J Brunetta4, B Trottier5, F Bonnet6, C Duvivier7, B van Welzen8, F Mack9, H Tossonian10, D Thorpe11, A Torres Cornejo12, A Marongiu11, R Curbelo13
![1009201](../images/100920/100920-6/1009201.gif)
![1009202](../images/100920/100920-6/1009202.gif)
![1009203](../images/100920/100920-6/1009203.gif)
![1009204](../images/100920/100920-6/1009204.gif)
![1009205](../images/100920/100920-6/1009205.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|